BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1142 related articles for article (PubMed ID: 19082859)

  • 1. Diffuse malignant peritoneal mesothelioma: Failure analysis following cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Baratti D; Kusamura S; Cabras AD; Dileo P; Laterza B; Deraco M
    Ann Surg Oncol; 2009 Feb; 16(2):463-72. PubMed ID: 19082859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lymph node metastases in diffuse malignant peritoneal mesothelioma.
    Baratti D; Kusamura S; Cabras AD; Laterza B; Balestra MR; Deraco M
    Ann Surg Oncol; 2010 Jan; 17(1):45-53. PubMed ID: 19856030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicystic and well-differentiated papillary peritoneal mesothelioma treated by surgical cytoreduction and hyperthermic intra-peritoneal chemotherapy (HIPEC).
    Baratti D; Kusamura S; Nonaka D; Oliva GD; Laterza B; Deraco M
    Ann Surg Oncol; 2007 Oct; 14(10):2790-7. PubMed ID: 17661150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion.
    Deraco M; Nonaka D; Baratti D; Casali P; Rosai J; Younan R; Salvatore A; Cabras Ad AD; Kusamura S
    Ann Surg Oncol; 2006 Feb; 13(2):229-37. PubMed ID: 16444562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC).
    Baratti D; Kusamura S; Cabras AD; Bertulli R; Hutanu I; Deraco M
    Eur J Cancer; 2013 Oct; 49(15):3140-8. PubMed ID: 23831335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicystic peritoneal mesothelioma: outcomes and patho-biological features in a multi-institutional series treated by cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
    Baratti D; Vaira M; Kusamura S; D'Amico S; Balestra MR; Cioppa T; Mingrone E; De Simone M; Deraco M
    Eur J Surg Oncol; 2010 Nov; 36(11):1047-53. PubMed ID: 20832234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer.
    Verwaal VJ; Bruin S; Boot H; van Slooten G; van Tinteren H
    Ann Surg Oncol; 2008 Sep; 15(9):2426-32. PubMed ID: 18521686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience.
    Yan TD; Deraco M; Baratti D; Kusamura S; Elias D; Glehen O; Gilly FN; Levine EA; Shen P; Mohamed F; Moran BJ; Morris DL; Chua TC; Piso P; Sugarbaker PH
    J Clin Oncol; 2009 Dec; 27(36):6237-42. PubMed ID: 19917862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peritoneal mesothelioma treated by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy: results of a prospective study.
    Brigand C; Monneuse O; Mohamed F; Sayag-Beaujard AC; Isaac S; Gilly FN; Glehen O
    Ann Surg Oncol; 2006 Mar; 13(3):405-12. PubMed ID: 16485159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multicystic peritoneal mesothelioma treated by surgical cytoreduction and hyperthermic intra-peritoneal chemotherapy (HIPEC).
    Baratti D; Kusamura S; Sironi A; Cabras A; Fumagalli L; Laterza B; Deraco M
    In Vivo; 2008; 22(1):153-7. PubMed ID: 18396799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of circulating tumor markers in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Baratti D; Kusamura S; Martinetti A; Seregni E; Laterza B; Oliva DG; Deraco M
    Ann Surg Oncol; 2007 Aug; 14(8):2300-8. PubMed ID: 17510772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pseudomyxoma peritonei: clinical pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Baratti D; Kusamura S; Nonaka D; Langer M; Andreola S; Favaro M; Gavazzi C; Laterza B; Deraco M
    Ann Surg Oncol; 2008 Feb; 15(2):526-34. PubMed ID: 18043976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peritoneal mesothelioma treated by induction chemotherapy, cytoreductive surgery, and intraperitoneal hyperthermic perfusion.
    Deraco M; Casali P; Inglese MG; Baratti D; Pennacchioli E; Bertulli R; Kusamura S
    J Surg Oncol; 2003 Jul; 83(3):147-53. PubMed ID: 12827682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I trial of pegylated liposomal doxorubicin with hyperthermic intraperitoneal chemotherapy in patients undergoing cytoreduction for advanced intra-abdominal malignancy.
    Harrison LE; Bryan M; Pliner L; Saunders T
    Ann Surg Oncol; 2008 May; 15(5):1407-13. PubMed ID: 18157576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Failure analysis of recurrent disease following complete cytoreduction and perioperative intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer.
    Bijelic L; Yan TD; Sugarbaker PH
    Ann Surg Oncol; 2007 Aug; 14(8):2281-8. PubMed ID: 17503156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recurrences after peritoneal carcinomatosis of colorectal origin treated by cytoreduction and hyperthermic intraperitoneal chemotherapy: location, treatment, and outcome.
    Verwaal VJ; Boot H; Aleman BM; van Tinteren H; Zoetmulder FA
    Ann Surg Oncol; 2004 Apr; 11(4):375-9. PubMed ID: 15070596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytoreductive surgery with selective versus complete parietal peritonectomy followed by hyperthermic intraperitoneal chemotherapy in patients with diffuse malignant peritoneal mesothelioma: a controlled study.
    Baratti D; Kusamura S; Cabras AD; Deraco M
    Ann Surg Oncol; 2012 May; 19(5):1416-24. PubMed ID: 22302266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer.
    Verwaal VJ; van Ruth S; de Bree E; van Sloothen GW; van Tinteren H; Boot H; Zoetmulder FA
    J Clin Oncol; 2003 Oct; 21(20):3737-43. PubMed ID: 14551293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Deraco M; Baratti D; Hutanu I; Bertuli R; Kusamura S
    Ann Surg Oncol; 2013 Apr; 20(4):1093-100. PubMed ID: 23456386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of peritoneal carcinomatosis from colonic cancer by cytoreduction, peritonectomy and hyperthermic intraperitoneal chemotherapy (HIPEC). Experience of ten years.
    Vaira M; Cioppa T; D'Amico S; de Marco G; D'Alessandro M; Fiorentini G; De Simone M
    In Vivo; 2010; 24(1):79-84. PubMed ID: 20133981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 58.